Purple Biotech Ltd
PPBT
$1.50
$0.010.33%
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -4.84% | -- | -- | |
| Gross Profit | -- | 4.84% | -- | -- | |
| SG&A Expenses | -12.59% | 116.94% | -21.04% | -38.06% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 5.10% | 191.63% | -62.04% | -68.52% | |
| Operating Income | -5.10% | -191.63% | 62.04% | 68.52% | |
| Income Before Tax | 140.50% | -5,596.87% | 54.91% | 87.94% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 140.50% | -5,596.87% | 54.91% | 87.94% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | 1,840.00% | -60.00% | -84.21% | |
| Net Income | 140.65% | -5,642.68% | 54.89% | 87.96% | |
| EBIT | -5.10% | -191.63% | 62.04% | 68.52% | |
| EBITDA | -3.36% | -188.83% | 62.92% | 69.19% | |
| EPS Basic | 110.00% | -890.00% | 77.01% | 93.53% | |
| Normalized Basic EPS | 108.33% | -33.33% | 76.00% | -- | |
| EPS Diluted | 110.00% | -890.00% | 77.01% | 93.53% | |
| Normalized Diluted EPS | 108.33% | -33.33% | 76.00% | -- | |
| Average Basic Shares Outstanding | 296.93% | 480.53% | 98.77% | 94.17% | |
| Average Diluted Shares Outstanding | 296.93% | 480.53% | 98.77% | 94.17% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |